Sandbox/v20: Difference between revisions
< Sandbox
Gerald Chi (talk | contribs) (Created page with " ====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin==== {| |- | valign=top | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: lef...") |
Gerald Chi (talk | contribs) |
||
Line 1: | Line 1: | ||
{{Meningitis}} | |||
====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin==== | ====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin==== | ||
Line 6: | Line 8: | ||
|- | |- | ||
| valign=top | | | valign=top | | ||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width: | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterococcus Susceptible to <BR> Penicillin, Gentamicin, and Vancomycin}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterococcus Susceptible to <BR> Penicillin, Gentamicin, and Vancomycin}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen (Adult)'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h x 4—6 weeks''''' <BR> ''OR'' <BR> ▸ '''''[[Penicillin G potassium]] 3—5 million U/day IV q4h x 4—6 weeks''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 4—6 weeks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen (Pediatric)'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h x 4—6 weeks''''' <BR> ''OR'' <BR> ▸ '''''[[Penicillin G potassium]] 3—5 million U/day IV q4h x 4—6 weeks''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 4—6 weeks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Alternative Regimen (Adult)''<sup>†</sup> | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 6 weeks''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 6 weeks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Alternative Regimen (Pediatric)''<sup>†</sup> | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 6 weeks''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 6 weeks''''' | ||
|- | |- | ||
|} | |} | ||
| valign=top | | | valign=top | | ||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width: | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:38em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}<sup>†</sup>'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}<sup>†</sup>'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]] 2 g IV q8h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|} | |} | ||
|} | |} | ||
Line 97: | Line 99: | ||
<sup>†</sup>Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected. | <sup>†</sup>Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected. | ||
<SMALL>Adapted from ''Advances in treatment of bacterial meningitis. Lancet. 2012; | <SMALL>Adapted from ''Advances in treatment of bacterial meningitis. Lancet. 2012;395(9854):1693-702.''</SMALL><ref name="van de Beek-2012">{{Cite journal | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. | title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 395 | issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref> |
Revision as of 21:27, 15 January 2014
Meningitis Main Page |
Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
|
|
†Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenes is also suspected.
Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;395(9854):1693-702.[1]